News Agency
Men's Weekly

Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca

  • Written by PR Newswire
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca

NATICK, Mass., Jan. 2, 2024 /PRNewswire/ -- Allorion Therapeutics ("Allorion"), a US and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, has entered into an exclusive option and global license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and...

Read more: Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel...

Air Conditioner Sales Melbourne Helping You Choose The Right Cooling Solution

Creating a comfortable indoor environment often starts with choosing the right system, and that’s where air conditioner sales Melbourne become more than just a purchase decision. It’s about finding a solution that aligns with your space, lifestyle, and energy needs. With... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion